Julian Baker’s Entrada Therapeutics TRDA Stock Holding History

Julian Baker’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.3M	Hold	5,072,730	–	–	0.19%	43
2026 Q1	$64M	Hold	5,072,730	–	–	0.37%	34
2025 Q4	$52.1M	Buy	5,072,730 +206,911	+4%	+$1.74M	0.31%	37
2025 Q3	$28.2M	Hold	4,865,819	–	–	0.2%	41
2025 Q2	$32.7M	Hold	4,865,819	–	–	0.32%	30
2025 Q1	$44M	Hold	4,865,819	–	–	0.49%	24
2024 Q4	$84.1M	Hold	4,865,819	–	–	0.9%	16
2024 Q3	$77.8M	Hold	4,865,819	–	–	0.81%	18
2024 Q2	$69.3M	Hold	4,865,819	–	–	0.89%	19
2024 Q1	$68.9M	Hold	4,865,819	–	–	0.86%	16
2023 Q4	$73.4M	Hold	4,865,819	–	–	0.84%	14
2023 Q3	$76.9M	Hold	4,865,819	–	–	0.44%	15
2023 Q2	$73.7M	Hold	4,865,819	–	–	0.43%	19
2023 Q1	$70.6M	Hold	4,865,819	–	–	0.38%	17
2022 Q4	$65.8M	Hold	4,865,819	–	–	0.4%	19
2022 Q3	$76.7M	Hold	4,865,819	–	–	0.5%	19
2022 Q2	$59.3M	Buy	4,865,819 +161,400	+3%	+$1.22M	0.34%	19
2022 Q1	$44.2M	Hold	4,704,419	–	–	0.25%	31
2021 Q4	$80.5M	Buy	+4,704,419	New	+$114M	0.39%	23

Other funds holding TRDA

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Julian Baker's TRDA Position: Q2 2026 in Review

Julian Baker held its Entrada Therapeutics (TRDA) position steady in Q2 2026 at 5,072,730 shares worth $37.3M. The position accounts for 0.19% of the portfolio, ranked #43.

Julian Baker first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $84.1M in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Julian Baker held 5,072,730 shares of Entrada Therapeutics worth $37.3M as of Q2 2026.
Julian Baker left its Entrada Therapeutics share count unchanged in Q2 2026.
Entrada Therapeutics made up 0.19% of Julian Baker's portfolio in Q2 2026, its #43 holding.
Julian Baker first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
Julian Baker's Entrada Therapeutics position peaked at $84.1M in Q4 2024.
128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Baker Bros. Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.